We are live on ! Find out more
RGC

Roberts, Glore & Co Portfolio holdings

AUM $364M
1-Year Est. Return 19.54%
This Fund
S&P 500
This Quarter Est. Return
-0.27%
1 Year Est. Return
+19.54%
3 Year Est. Return
+59.43%
5 Year Est. Return
+77.93%
10 Year Est. Return
+273.65%
AUM
$337M
AUM Growth
-$8.73M
Cap. Flow
-$4.66M
Cap. Flow %
-1.38%
Top 10 Hldgs %
36.68%
Holding
216
New
7
Increased
44
Reduced
112
Closed
8

Top Buys

Rank Stock Value
1
ASML icon
ASML
ASML
+$732K
2
ELV icon
Elevance Health
ELV
+$644K
3
ADBE icon
Adobe
ADBE
+$573K
4
VBR icon
Vanguard Morningstar Small-Cap Value ETF
VBR
+$510K
5
NKE icon
Nike
NKE
+$337K

Sector Composition

Rank Sector Weight
1 Technology 18.56%
2 Healthcare 15.23%
3 Financials 13.1%
4 Industrials 8.56%
5 Communication Services 7.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EXPD icon
26
Expeditors International
EXPD
$22.1B
$3.03M 0.9%
27,366
-562
-2% -$67.1K
VBR icon
27
Vanguard Morningstar Small-Cap Value ETF
VBR
$37.1B
$2.95M 0.88%
14,887
+2,486
+20% +$510K
NSC icon
28
Norfolk Southern
NSC
$75.5B
$2.73M 0.81%
11,627
-150
-1% -$38.1K
META icon
29
Meta Platforms (Facebook)
META
$1.39T
$2.57M 0.76%
4,381
-21
-0.5% -$12.3K
XOM icon
30
ExxonMobil
XOM
$635B
$2.55M 0.76%
23,726
-80
-0.3% -$9.36K
SBUX icon
31
Starbucks
SBUX
$120B
$2.53M 0.75%
27,687
-340
-1% -$32.9K
MGV icon
32
Vanguard Morningstar Mega Cap Value ETF
MGV
$13.2B
$2.38M 0.71%
19,065
-21
-0.1% -$2.71K
VIG icon
33
Vanguard Dividend Appreciation ETF
VIG
$111B
$2.32M 0.69%
11,863
-38
-0.3% -$7.59K
VCSH icon
34
Vanguard Short-Term Corporate Bond ETF
VCSH
$44.7B
$2.3M 0.68%
29,535
+250
+0.9% +$19.6K
LIN icon
35
Linde
LIN
$222B
$2.25M 0.67%
5,386
-95
-2% -$43.3K
DGX icon
36
Quest Diagnostics
DGX
$25.9B
$2.18M 0.65%
14,439
-217
-1% -$33.8K
PG icon
37
Procter & Gamble
PG
$335B
$2.15M 0.64%
12,816
-543
-4% -$92.5K
UNP icon
38
Union Pacific
UNP
$174B
$2.08M 0.62%
9,129
-32
-0.3% -$7.58K
AMGN icon
39
Amgen
AMGN
$207B
$2.05M 0.61%
7,869
+7
+0.1% +$2.08K
PYPL icon
40
PayPal
PYPL
$48.7B
$1.98M 0.59%
23,142
+185
+0.8% +$15.6K
CNC icon
41
Centene
CNC
$30.7B
$1.97M 0.59%
32,592
+2,270
+7% +$142K
ADX icon
42
Adams Diversified Equity Fund
ADX
$3.1B
$1.96M 0.58%
97,205
+9,288
+11% +$198K
MTB icon
43
M&T Bank
MTB
$35.9B
$1.95M 0.58%
10,385
-133
-1% -$26.4K
ETR icon
44
Entergy
ETR
$50.7B
$1.95M 0.58%
25,740
-126
-0.5% -$9.1K
BKNG icon
45
Booking.com
BKNG
$150B
$1.95M 0.58%
9,800
-25
-0.3% -$4.8K
BDX icon
46
Becton Dickinson
BDX
$45.3B
$1.93M 0.57%
8,494
+110
+1% +$25.4K
VOO icon
47
Vanguard S&P 500 ETF
VOO
$973B
$1.88M 0.56%
3,486
+4
+0.1% +$2.17K
VIGI icon
48
Vanguard International Dividend Appreciation ETF
VIGI
$9.08B
$1.87M 0.55%
23,331
+1,299
+6% +$109K
DFSV
49
Dimensional US Small Cap Value ETF
DFSV
$8.16B
$1.87M 0.55%
60,606
+5,111
+9% +$162K
TECH icon
50
Bio-Techne
TECH
$11.2B
$1.85M 0.55%
25,686
-234
-0.9% -$17.2K

Similar funds

Roberts, Glore & Co's Q4 2024 Portfolio in Review

As of Q4 2024, Roberts, Glore & Co held 216 positions worth $337M, down 2.5% from $346M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Roberts, Glore & Co's Q4 2024 filing shows 7 new, 44 increased, 112 reduced and 8 closed positions. Its largest new stake was ASML: 1,020 shares worth $707K. The largest sale was CVS Health, an estimated $906K.

By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.

  • Roberts, Glore & Co's largest Q4 2024 buy was ASML: 1,020 shares worth $707K.
  • Roberts, Glore & Co added most to Elevance Health in Q4 2024, an estimated $644K increase.
  • Roberts, Glore & Co's biggest Q4 2024 reduction was CVS Health, cutting an estimated $906K.
  • Roberts, Glore & Co fully exited Estee Lauder in Q4 2024, selling an estimated $507K.
  • Roberts, Glore & Co's ten largest holdings make up 37% of its $337M portfolio in Q4 2024.
  • Roberts, Glore & Co opened 7 new positions and closed 8 in Q4 2024.
  • Roberts, Glore & Co's portfolio value fell 2.5% quarter-over-quarter to $337M.

Based on Roberts, Glore & Co's 13F filing for Q4 2024, filed 7 Feb 2025.